Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, it is developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL and targeting B-cell maturation antigen for the treatment of MM, which are currently in an investigator-initiated Phase 1 clinical trial in China. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases.
Legend Biotech
Unlock to Claim this listing
Add / Modify Company
0.00
Overall Excellence Rating
Industry
Pharmaceuticals & BiotechnologyCategory
Biotechnology ResearchESG/Ethical Impact
Legend Biotech Corporation forges a path of environmental stewardship through holistic strategies that imbue sustainability throughout its operations, encompassing energy-efficient facilities, responsible sourcing, waste reduction initiatives, and eco-friendly packaging solutions, harmoniously interweaving its commitment to scientific innovation with its responsibility to minimize its environmental footprint and catalyze a culture of environmental consciousness. Legend Biotech Corporation manifests its profound commitment to bettering lives through transformative therapies, channeling its pioneering product portfolio toward addressing unmet medical needs, while actively engaging in patient advocacy, community collaborations, and healthcare education endeavors, thereby cultivating a comprehensive approach to societal well-being that transcends conventional boundaries. Social determinants of health — issues that affect individuals’ abilities to access quality healthcare such as financial concerns, affordable medication, food insecurity, and lack of transportation — pose significant barriers for patients seeking quality healthcare services. The financial sustainability of Legend Biotech Corporation is seamlessly intertwined with its holistic ESG imperatives, as its financial growth finds synergy with its ability to develop and deliver pioneering therapies that resonate with patients, healthcare professionals, and investors attuned to the intrinsic worth of responsible innovation and sustainable business practices. Signify Health is a leading healthcare platform that leverages advanced analytics, technology and nationwide provider networks to create and power value-based payment programs. Our solutions align financial incentives around outcomes, providing tools to health plans and healthcare organizations designed to assess and manage risk and identify actionable opportunities for improved patient outcomes, coordination, and cost-savings. Legend Biotech Corporation’s unwavering dedication to innovation and research excellence anchors its ESG sustainability strategy, as it relentlessly forges ahead with therapies addressing critical medical challenges, elevating patient outcomes, and propelling medical science into the future, steadfastly upholding the highest ethical standards, research integrity, and a resolute commitment to pioneering advancements in healthcare.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us
Awards Received
2023
Revenues
123000000.00
Website Traffic
Employee Rating
3.70
Customer Rating
2.90
Company Size
1000-5000
ESG Risk Rating
1.00